Follow us on:

Linkedin Facebook

GlaxoSmithKline plc 0.3% Potential Decrease Indicated by Deutsche Bank

Broker Ratings

GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Deutsche Bank. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 1550 GBX on its stock. This would imply the analyst believes there is a potential downside of -.3% from the opening price of 1555.2 GBX. Over the last 30 and 90 trading days the company share price has decreased 32.4 points and increased 73.4 points respectively. The 1 year high for the share price is 1648.8 GBX while the 52 week low for the share price is 1274.33 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,556.32 GBX and a 200 Day Moving Average share price is recorded at 1,546.65. There are currently 4,987,785,834 shares in issue with the average daily volume traded being 8,432,452. Market capitalisation for LON:GSK is £77,998,997,307 GBP.

Share on:
Find more news, interviews, share price & company profile here for:

    Latest Company News

    GSK plc

    GSK Plc 5-in-1 meningococcal vaccine approved by FDA

    GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.
    GSK Plc

    GSK Plc reports strong growth in Specialty Medicines and R&D progress

    GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.
    GSK

    GSK plc Depemokimab applications accepted for review in China and Japan

    GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
    GSK Shingrex

    GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

    GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.
    GSK

    GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

    GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.
    GSK Shingrex

    FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

    GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers.

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.